The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more ...

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal ...

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...